Neurocrine Biosciences Inc (NBIX)
125.00
+1.71
(+1.39%)
USD |
NASDAQ |
Nov 21, 16:00
123.15
-1.85
(-1.48%)
After-Hours: 20:00
Neurocrine Biosciences Debt to Equity Ratio: 0.00 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.1085 |
| December 31, 2023 | 0.0762 |
| September 30, 2023 | 0.0849 |
| June 30, 2023 | 0.0916 |
| March 31, 2023 | 0.1006 |
| December 31, 2022 | 0.0992 |
| September 30, 2022 | 0.1095 |
| June 30, 2022 | 0.1187 |
| March 31, 2022 | 0.2715 |
| December 31, 2021 | 0.2439 |
| September 30, 2021 | 0.2457 |
| June 30, 2021 | 0.2551 |
| March 31, 2021 | 0.2671 |
| December 31, 2020 | 0.2823 |
| September 30, 2020 | 0.5284 |
| June 30, 2020 | 0.5047 |
| March 31, 2020 | 0.5913 |
| December 31, 2019 | 0.6419 |
| September 30, 2019 | 0.7025 |
| June 30, 2019 | 0.8238 |
| March 31, 2019 | 0.9613 |
| December 31, 2018 | 0.8081 |
| September 30, 2018 | 0.8573 |
| Date | Value |
|---|---|
| June 30, 2018 | 1.004 |
| March 31, 2018 | 1.027 |
| December 31, 2017 | 0.9932 |
| September 30, 2017 | 1.051 |
| June 30, 2017 | 1.045 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
| December 31, 2013 | 0.00 |
| September 30, 2013 | 0.00 |
| June 30, 2013 | 0.00 |
| March 31, 2013 | 0.00 |
| December 31, 2012 | 0.00 |
| September 30, 2012 | 0.00 |
| June 30, 2012 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Jun 2024
0.6419
Maximum
Dec 2019
0.2311
Average
0.1813
Median
Debt to Equity Ratio Benchmarks
| Repligen Corp | 0.2586 |
| West Pharmaceutical Services Inc | 0.0736 |
| Bruker Corp | 1.271 |
| The Cooper Companies Inc | 0.3317 |
| Integra Lifesciences Holdings Corp | 1.187 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 3.535B |
| Total Liabilities (Quarterly) | 816.10M |
| Shareholders Equity (Quarterly) | 2.719B |
| Current Ratio | 4.367 |
| Net Debt Paydown Yield | 0.29% |